377 related articles for article (PubMed ID: 34128827)
1. Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer.
Mitsiades N; Kaochar S
Endocr Relat Cancer; 2021 Jul; 28(8):T19-T38. PubMed ID: 34128827
[TBL] [Abstract][Full Text] [Related]
2. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
3. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
4. Hormonal Therapy for Prostate Cancer.
Desai K; McManus JM; Sharifi N
Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
[TBL] [Abstract][Full Text] [Related]
7. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
8. Resistance to Hormonal Therapy in Prostate Cancer.
Berruti A; Dalla Volta A
Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
[TBL] [Abstract][Full Text] [Related]
10. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
11. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
[TBL] [Abstract][Full Text] [Related]
12. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
[TBL] [Abstract][Full Text] [Related]
13. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Zhang X; Zhang G; Wang J; Bi J
Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606
[TBL] [Abstract][Full Text] [Related]
15. Second generation androgen receptor antagonists and challenges in prostate cancer treatment.
Chen Y; Zhou Q; Hankey W; Fang X; Yuan F
Cell Death Dis; 2022 Jul; 13(7):632. PubMed ID: 35864113
[TBL] [Abstract][Full Text] [Related]
16. Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management.
Tartarone A; Lerose R; Tartarone M
Med Oncol; 2022 May; 39(7):107. PubMed ID: 35553247
[TBL] [Abstract][Full Text] [Related]
17. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
Conde-Estévez D; Henríquez I; Muñoz-Rodríguez J; Rodriguez-Vida A
Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):601-613. PubMed ID: 36111393
[TBL] [Abstract][Full Text] [Related]
18. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
Antonarakis ES; Chandhasin C; Osbourne E; Luo J; Sadar MD; Perabo F
Oncologist; 2016 Dec; 21(12):1427-1435. PubMed ID: 27628492
[TBL] [Abstract][Full Text] [Related]
19. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
Mitsiades N
Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]